The leader in adaptive PCR diagnostics.

As your insurance policy against the unknown, our revolutionary detection and genotyping technology – PANDAA – uniquely compensates for evolving pathogen diversity, ensuring that PCR diagnostic integrity isn’t affected by genomic variation now, or in the future.

Learn more

WHat we do

As a public benefit corporation, our goal is to advance infectious disease diagnostics that facilitate society's collective response to global health emergencies.

An innovative platform for target detection in highly variable genomic regions

Aldatu Biosciences has established the Pan Degenerate Amplification and Adaptation (PANDAA™) platform to enable target detection in highly variable genomic regions with RT-PCR. Our proprietary PANDAA technology allows the development of fast, reliable, and cost-effective diagnostic tests for infectious diseases.

Our pipeline includes products for the detection of SARS-CoV-2, Lassa virus, and drug-resistant HIV variants. The high-throughput, low-cost PANDAA platform improves patient healthcare access and outcomes. 

Aldatu Biosciences has established the Pan Degenerate Amplification and Adaptation (PANDAA™) platform to enable target detection in highly variable genomic regions with RT-PCR. Our proprietary PANDAA technology allows the development of fast, reliable, and cost-effective diagnostic tests for infectious diseases.

Our pipeline includes products for the detection of SARS-CoV-2, Lassa virus, and drug-resistant HIV variants. The high-throughput, low-cost PANDAA platform improves patient healthcare access and outcomes. 

As first-ever Marburg outbreak in Tanzania evolves, Aldatu leads the way with pan-filovirus testing for universal access.​

Aldatu Biosciences, a biotechnology company developing molecular diagnostic assays and products based on gold standard real-time PCR, today announced it has been awarded a $3 Million Direct-to-Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). The award will fund the continued advancement of the company’s proprietary PANDAA™ technology platform and its specific application to the universal, pan-lineage detection of Crimean-Congo Hemorrhagic Fever Virus (CCHFV), the causative agent of Crimean Congo Hemorrhagic Fever (CCHF).

Read More »

Aldatu Biosciences Adds Another Outbreak Disease to Pandemic Preparedness Portfolio

Aldatu Biosciences, a biotechnology company developing molecular diagnostic assays and products based on gold standard real-time PCR, today announced it has been awarded a $3 Million Direct-to-Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). The award will fund the continued advancement of the company’s proprietary PANDAA™ technology platform and its specific application to the universal, pan-lineage detection of Crimean-Congo Hemorrhagic Fever Virus (CCHFV), the causative agent of Crimean Congo Hemorrhagic Fever (CCHF).

Read More »

Senior Research Associate

The Person and Role We are seeking highly-motivated and talented senior research associate to join our Assay Development team. Successful applicants will possess strong molecular biology skills and a demonstrated interest in global health and / or infectious disease. Our

Read More »

ACCOUNT

OUR COMPANY

RESOURCES

Facebook-f Twitter Linkedin-in

© 2021 ALDATU BIOSCIENCES 2021.